Skip to main content
GILD
NASDAQ Life Sciences

Gilead's Livdelzi Phase 3 Study Shows Sustained Efficacy, No New Safety Concerns

Tom Rudovsky · Reported by Reuters
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$133.5
Mkt Cap
$166.035B
52W Low
$104.46
52W High
$157.29
52W Position info
28% above low
Off High info
15% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

GILD sits 28% above its 52-week low of $104.46.

Summary

Gilead announced positive further analyses from its Phase 3 ASSURE study for Livdelzi, demonstrating sustained ALP normalization in PBC patients. The drug was also generally well tolerated with no new safety signals observed over two years. This positive late-stage clinical data strengthens Gilead's pipeline and de-risks a potential new treatment, following a period of significant M&A and financing activities for the company.

At the time of this announcement, GILD was trading at $133.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $166B. The 52-week trading range was $104.46 to $157.29. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

GILD - Latest Insights

GILD
Nov 06, 2026, 12:16 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $167.82
Real-time Price: $169.72 info
Change: +$1.91 (+1%) info
Market Cap: $210.609B info
GILD
Nov 05, 2026, 10:35 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $174.57
Real-time Price: $169.72 info
Change: -$4.84 (-3%) info
Market Cap: $210.609B info
GILD
Oct 29, 2026, 4:03 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $165.88
Real-time Price: $169.72 info
Change: +$3.84 (+2%) info
Market Cap: $210.609B info
GILD
Oct 29, 2026, 4:02 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $164.00
Real-time Price: $169.72 info
Change: +$5.72 (+3%) info
Market Cap: $210.609B info
GILD
Oct 22, 2026, 4:05 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $157.19
Real-time Price: $169.72 info
Change: +$12.53 (+8%) info
Market Cap: $210.609B info